Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.36 |
| ▸ | CDK9 | P50750 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2883039 | 1.00 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3HTR6HTR1A | |
| SCHEMBL1020818 | 0.80 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3HTR6HTR1A | |
| SCHEMBL1020817 | 0.80 | SLC6A2 (0.69) | SLC6A2SLC6A4SLC6A3HTR6HTR1A | |
| Hydrochloric Acid SCHEMBL1023640 | 0.79 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3HTR6HTR1A | |
| SCHEMBL1335541 | 0.77 | SLC6A4 (0.58) | SLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL2880793 | 0.77 | WDR5 (0.42) | HSD11B1CCNT1CDK9 | |
| SCHEMBL2880799 | 0.77 | WDR5 (0.42) | HSD11B1CCNT1CDK9 | |
| SCHEMBL8106669 | 0.76 | SLC6A4 (0.70) | SLC6A2SLC6A4SLC6A3HTR6HTR1A | |
| SCHEMBL8106666 | 0.76 | SLC6A4 (0.70) | SLC6A2SLC6A4SLC6A3HTR6HTR1A | |
| SCHEMBL5830039 | 0.76 | SLC6A4 (0.58) | SLC6A2SLC6A4SLC6A3HTR6HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | SLC6A2 150/4885SLC6A4 241/4885SLC6A3 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.